gefitinib drug pathway gefitinib pharmacodynamics pathway 2011-06-09T05:31:16Z PW:0000871 SMP:00473 The pathway of gefitinib-target interactions and of the biochemical or physiological responses to drug. Gefitinib is the first selective inhibitor of EGFR whose mutations within the tyrosine kinase domain have been associated with hyperactive epidermal growth factor signaling in non-small cell lung cancers. Genetic variations can cause differences in the response of the organism to the drug. pathway vpetri